A- A A+

Crystal methamphetamine use and methadone maintenance treatment dissatisfaction: A prospective cohort study in Vancouver, Canada. 

Cui Z, Hayashi K, Bach P, Milloy MJ, Kerr T. 

J Subst Use Addict Treat. 2023 Jan 18:208956. doi: 10.1016/j.josat.2023.208956. Epub ahead of print. PMID: 36804867.

Abstract

https://www.sciencedirect.com/science/article/abs/pii/S2949875923000061

Analysis of Methadone and EDDP in Addicted Patients under Methadone Substitution Treatment: Comparison of Urine and Plasma as Biological Samples. 

Ciucă Anghel DM, Ciobanu AM, Guțu CM, Stan M, Tudor G, Baconi DL. GC-MS 

Molecules. 2022 Nov 30;27(23):8360. doi: 10.3390/molecules27238360. PMID: 36500452; PMCID: PMC9739625.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739625/

Psychosocial combined with methadone maintenance treatments versus methadone maintenance treatments alone for treatment of opioid use disorder: A meta-analysis. 

Liu C, Li Y. 

J Addict Dis. 2023 Jan 6:1-10. doi: 10.1080/10550887.2022.2158664. Epub ahead of print. PMID: 36607171.

Abstract

https://pubmed.ncbi.nlm.nih.gov/36607171/

CYP genetic polymorphism, pharmacokinetics of methadone, and the biggest risks

Jovanovic M., Bozovic N., Rancic N., Pjevac A., Rascanin S., and Stojkovic M.

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, December 3, 2022

https://www.heroinaddictionrelatedclinicalproblems.org/download-article.php?idarticolodoi=Adoi0000362

The effect of a methadone-initiated memory reconsolidation updating procedure in opioid use disorder: A translational study. 

Yue JL, Yuan K, Bao YP, Meng SQ, Shi L, Fang Q, Guo XJ, Cao L, Sun YK, Lu TS, Zeng N, Yan W, Han Y, Sun J, Shi J, Kosten TR, Xue YX, Wu P, Lu L. 

EBioMedicine. 2022 Nov;85:104283. doi: 10.1016/j.ebiom.2022.104283. Epub 2022 Sep 28. PMID: 36182773; PMCID: PMC9525804.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525804/

Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response. 

Xie X, Gu J, Zhuang D, Zhou Y, Chen X, Shen W, Li L, Liu Y, Xu W, Hong Q, Xu Z, Chen W, Zhou W, Liu H. 

J Clin Lab Anal. 2022 Nov;36(11):e24750. doi: 10.1002/jcla.24750. Epub 2022 Oct 28. PMID: 36305091; PMCID: PMC9701885.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701885/

The therapeutic effect of N-acetylcysteine as an add-on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double-blind, placebo-controlled clinical trial. 

Padoei F, Mamsharifi P, Hazegh P, Boroumand H, Ostadmohammady F, Abbaszadeh-Mashkani S, Banafshe HR, Matini AH, Ghaderi A, Dehkohneh SG. 

Brain Behav. 2022 Nov 30:e2823. doi: 10.1002/brb3.2823. Epub ahead of print. PMID: 36448959.

https://onlinelibrary.wiley.com/doi/10.1002/brb3.2823

Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. 

Kharasch ED, Regina KJ, Blood J, Friedel C. 

Anesthesiology. 2015 Nov;123(5):1142-53. doi: 10.1097/ALN.0000000000000867. PMID: 26389554; PMCID: PMC4667947.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667947/

Methadone-induced hypoglycemia: A case report. 

Malboosbaf R, Hatami N, Maghsoomi Z. 

J Diabetes Investig. 2022 Oct 6. doi: 10.1111/jdi.13919. Epub ahead of print. PMID: 36201002.

https://onlinelibrary.wiley.com/doi/10.1111/jdi.13919

Decision tree model based prediction of the efficacy of acupuncture in methadone maintenance treatment. 

Dong Y, Fan B, Yan E, Chen R, Wei X, Zhan J, Zeng J, Wen H, Lu L. 

Front Neurol. 2022 Oct 6;13:956255. doi: 10.3389/fneur.2022.956255. PMID: 36277917; PMCID: PMC9582273.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582273/

Neurological Manifestations of Chronic Methadone Maintenance Therapy: A Case Report and Literature Review. 

Gasimova U, Afzal KM, Acharya AB. 

Cureus. 2022 Sep 24;14(9):e29534. doi: 10.7759/cureus.29534. PMID: 36312663; PMCID: PMC9595224.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595224/

Transitioning From High-dose Methadone to Buprenorphine Using a Microdosing Approach: Unique Considerations at ASAM Level 3 Facilities. 

Anderson C, Cooley R, Patil D. 

J Addict Med. 2022 Sep 26. doi: 10.1097/ADM.0000000000001085. Epub ahead of print. PMID: 36161824.

Abstract

https://pubmed.ncbi.nlm.nih.gov/36161824/

2-Minute Neuroscience: Methadone (Video)

Methadone is commonly used to treat opioid use disorder even though its pharmacological action is very similar to that of other opioids like morphine. In this video, I discuss the qualities that make methadone an effective treatment for opioid addiction, along with how it acts to reduce the risks associated with opioid abuse. (Neuroscientifically Challenged, 07.06.2019, Video, 01:58)

https://www.youtube.com/watch?v=dw6laQ4-Zgs

REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats. 

Henningfield J, Gauvin D, Bifari F, Fant R, Shram M, Buchhalter A, Ashworth J, Lanier R, Pappagallo M, Inturrisi C, Folli F, Traversa S, Manfredi PL. 

Sci Rep. 2022 Jul 6;12(1):11389. doi: 10.1038/s41598-022-15055-3. PMID: 35794162; PMCID: PMC9259683.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259683/

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.

Sadek J, Saunders J. 

BMC Psychiatry. 2022 Jul 30;22(1):516. doi: 10.1186/s12888-022-04175-9. PMID: 35908052; PMCID: PMC9338516.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338516/

Sex differences in weight gain during medication-based treatment for opioid use disorder: A meta-analysis and retrospective analysis of clinical trial data. 

Manza P, Kroll D, McPherson KL, Johnson A, Dennis E, Hu L, Tai B, Volkow ND. 

Drug Alcohol Depend. 2022 Jul 16;238:109575. doi: 10.1016/j.drugalcdep.2022.109575. Epub ahead of print. PMID: 35868182.

Abstract

https://www.sciencedirect.com/science/article/abs/pii/S037687162200312X

A Review of Novel Methods To Support The Transition From Methadone and Other Full Agonist Opioids To Buprenorphine/Naloxone Sublingual In Both Community and Acute Care Settings,

Ghosh, Sumantra Monty MD, MSc, FRCPC, ISAM1; Klaire, Sukhpreet MD, CCFP2; Tanguay, Robert MD, FRCPC, ISAM3; Manek, Mandy MD, CCFP4; Azar, Pouya MD, FRCPC, ISAM5

The Canadian Journal of Addiction: December 2019 - Volume 10 - Issue 4 - p 41-50, doi: 10.1097/CXA.0000000000000072

https://journals.lww.com/cja/fulltext/2019/12000/a_review_of_novel_methods_to_support_the.7.aspx

Treatment Choices: Methadone

Exchange Supplies, UK. Third edition. oD

https://www.exchangesupplies.org/pdf/P801_1.pdf

The Methadone Handbook - Thirteenth edition

Written by: Andrew Preston 

Published by: Exchange Supplies, Illustrations: Michael Linnell

© Exchange Supplies. ISBN 0 9520600 5 1

https://www.exchangesupplies.org/pdf/P301_13_2021.pdf

The Effects of Probiotic Supplementation on Opioid-Related Disorder in Patients under Methadone Maintenance Treatment Programs. 

Molavi N, Rasouli-Azad M, Mirzaei H, Matini AH, Banafshe HR, Valiollahzadeh M, Hassanzadeh M, Saghazade AR, Abbaszadeh-Mashkani S, Mamsharifi P, Ghaderi A. 

Int J Clin Pract. 2022 Mar 30;2022:1206914. doi: 10.1155/2022/1206914. PMID: 35685534; PMCID: PMC9159114.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159114/

Laser meridian massage decreased craving in men with opioid use disorder on methadone maintenance treatment. 

Hu WL, Tsai MC, Kuo CE, Liu CT, Wu SY, Wu TC, Hung YC. 

Biomed J. 2021 May 1:S2319-4170(21)00042-1. doi: 10.1016/j.bj.2021.04.010. Epub ahead of print. PMID: 35595647.

https://www.sciencedirect.com/science/article/pii/S2319417021000421

Investigating Cognitive Functions in Methadone Users in Comparison with Methadone and Methamphetamine Users and Control Group. 

Eslami-Shahrbabaki M, Barfehee D, Parvaresh N, Zamani E, Soltaninejad A, Ahmadi A. 

Addict Health. 2022 Jan;14(1):1-6. doi: 10.22122/ahj.v14i1.292. PMID: 35573763; PMCID: PMC9057645.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057645/

Side Effects from Chronic Methadone Use in Opioid Addiction: A Scoping Review on Hematological Derangements. 

Khalid K, Anuar A, Ang WC, Jamaluddin R. 

Curr Drug Saf. 2022 May 14. doi: 10.2174/1574886317666220514154931. Epub ahead of print. PMID: 35570535.

Abstract

https://pubmed.ncbi.nlm.nih.gov/35570535/

Identifying relative strength of methadone versus health and social services in comprehensive substance use disorder treatment using a variance decomposition approach. 

Shin HC, Marsh JC. 

Eval Program Plann. 2022 Feb 23;92:102060. doi: 10.1016/j.evalprogplan.2022.102060. Epub ahead of print. PMID: 35247677.

https://www.sciencedirect.com/science/article/pii/S0149718922000143?via%3Dihub

USA. Methadone: An American Way of Dealing (Video)

Klein and Richert’s camera contrasts a state-operated methadone clinic in Dayton, Ohio, with Washington, DC’s Afrocentric RAP therapeutic community, founded in 1970 by Ron Clark, a veteran of LA’s Synanon. (pointshistory.com, USA, 01.02.2022, Video, 01:05:56)

https://pointshistory.com/2022/02/01/methadone-marathon-intro/

USA. The Points Methadone Marathon

Welcome to the home page for the Points Methadone Marathon! (pointshistory.com, USA, 01.02.2022)

https://pointshistory.com/2022/02/01/methadone-marathon-intro/

The effect of a methadone reformulation on opioid agonist treatment outcomes: A population-based study in British Columbia, Canada, 2013-14. 

Krebs E, Hongdilokkul N, Dale LM, Min JE, Schnepel KT, Shigeoka H, Nosyk B. 

J Subst Abuse Treat. 2021 Dec 28:108714. doi: 10.1016/j.jsat.2021.108714. Epub ahead of print. PMID: 35101357.

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(21)00440-2/fulltext

Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences. 

Chawar C, Hillmer A, Lamri A, Kapczinski F, Thabane L, Pare G, et al. (2021) 

PLoS ONE 16(12): e0261201. doi.org/10.1371/journal.pone.0261201

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0261201

Different drugs come with different motives: Examining motives for substance use among people who engage in polysubstance use undergoing methadone maintenance therapy (MMT). 

Mahu IT, Barrett SP, Conrod PJ, Bartel SJ, Stewart SH. 

Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109133. doi: 10.1016/j.drugalcdep.2021.109133. Epub 2021 Oct 30. PMID: 34768142.

https://www.sciencedirect.com/science/article/pii/S0376871621006281

The influence of methadone on cerebral gray matter and functional connectivity. 

Zhu J, Wang S, Liu Y, Wang F, Li Q, Li Z, Sun Y, Li W, Wang W. 

Ann Palliat Med. 2021 Sep;10(9):9497-9507. doi: 10.21037/apm-21-2012. PMID: 34628875.

https://apm.amegroups.com/article/view/79702/html

  1. Methadone vs. Buprenorphine for In-Hospital Initiation: Which Is Better for Outpatient Care Retention in Patients with Opioid Use Disorder? 
  2. Risk of motor vehicle collisions after methadone use. 
  3. Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment. 
  4. Gender disparities in opioid treatment progress in methadone versus counseling. 
  5. Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway.